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Abstract
Background: Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having
Alzheimer’s disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to
a memory clinic, by assessing the factors associated with increased AD risk.
Methods: Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst
which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community; n = 23) or from a
memory clinic (SCD-clinic; n = 27). Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and
amyloid-PET assessments. They were followed up over a mean period of 2.4 ± 0.8 years. The groups were compared
in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and
depression, and atrophy progression over time. We also investigated SCD substrates within each SCD group
through the correlations between self-reported SCD and other psychometric and brain measures.
Results: Compared to HC, both SCD groups showed similar cognitive performances but higher informant-reported
SCD and anxiety. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression
score, and atrophy progression over time but similar brain amyloid load. A significant increase over time was found
for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic.
Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii)
greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups.
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Conclusions: Higher subclinical depression and informant-reported SCD specifically characterize the SCD group
that refers to a memory clinic. The same group appears as a frailer population than SCD-community as they show
greater atrophy progression over time. Yet, both the SCD groups were quite similar otherwise including for brain
amyloid load and the SCD-community showed increased depression score over time. Altogether, our findings
highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and
point to both differences and similarities in SCD populations referring or not to a memory clinic.
Keywords: Neuroimaging, Biomarkers, Pathological ageing, Preclinical Alzheimer’s disease, Psychoaffective factors,
Subjective cognitive decline
Background
Subjective cognitive decline (SCD) refers to individuals’
perceived decline in memory and/or other cognitive abil-
ities relative to their previous level of performance, in the
absence of objective neuropsychological deficits [1].
Although these individuals have been described for de-
cades [2], they have received increasing attention over the
past few years due to growing interest in characterizing the
preclinical stages of Alzheimer’s disease (AD) [3, 4]. Recent
cross-sectional studies have shown that SCD is associated
with neuroimaging biomarkers suggestive of AD such as
hippocampal/parahippocampal atrophy [5–17] and/or
temporoparietal hypometabolism [5, 18, 19], and cortical
amyloid β (Aβ) deposition [18, 20–24] (see [25] for review).
Longitudinal investigations have repeatedly shown that
SCD is also associated with an increased risk of subsequent
cognitive decline [26, 27] or conversion to mild cognitive
impairment (MCI) or AD dementia [28–34]. There is thus
converging evidence that SCD is associated with an
increased risk of AD dementia and might represent, at
least for some cases, the first clinically observable sign of
Alzheimer’s clinical syndrome [35].
However, the links between SCD and AD biomarkers
have not been reported in all studies (see [25] for
review), which might reflect the fact that SCD is multi-
determined. Thus, SCD may be due to AD but also non-
AD aetiologies (see [36] for review, [37]) including
normal ageing [38], poor general health [38, 39], medica-
tion [1], sleep disorders [40–43], or psychoaffective
factors such as anxiety and depression [39–41, 44]. The
current challenge, as highlighted in an international
collaborative working group on SCD called the SCD-Ini-
tiative (SCD-I; [1, 45]), is thus to identify the specific
characteristics of SCD that are associated with an in-
creased likelihood of AD aetiology [1, 45].
An important source of heterogeneity in the definition
and aetiology of SCD patients is their type of recruit-
ment [25] (see [46–48] for review). Indeed, typical re-
search settings include population-based studies [6, 24],
volunteer samples [18, 20, 21, 23], and/or medical help-
seeking samples [5, 7–12, 22]. In a previous study [25],
we showed that SCD patients who refer to a memory
clinic, referred to as SCD-clinic, had significant atrophy in
AD-sensitive regions compared to SCD individuals re-
cruited from a self-reported SCD questionnaire in volun-
teers from the community, referred to as SCD-community
in what follows. This previous study suggested that SCD-
clinic as a group is further along the Alzheimer’s clinical
syndrome trajectory than SCD-community.
In this study, our aim was to provide further evi-
dence towards this statement with a more complete
characterization of both SCD-clinic and SCD-commu-
nity populations of the substrates of their SCD and of
their evolution.
For this purpose, we first highlighted the similarities
and differences between the two SCD populations in
terms of cognitive performances, psychoaffective mea-
sures, informant-reported SCD, and the type of self-
reported SCD. Informant-reported SCD is recognized
as a feature that influences the likelihood of preclinical
AD/Alzheimer’s syndrome—confirmation of cognitive
decline by an informant being associated with in-
creased risk for preclinical AD/Alzheimer’s syndrome
[1, 45, 49, 50]. Moreover, subclinical symptoms of anx-
iety or depression might be related with SCD and may
constitute risk factors for subsequent cognitive decline
and/or be early manifestations of preclinical Alzhei-
mer’s syndrome [51–55]. In addition, a previous study
showed that SCD of different cognitive domains were
differentially associated with preclinical Alzheimer’s
syndrome [56].
Second, we investigated the substrates of self-reported
SCD within each SCD group by assessing the correla-
tions with informant-reported SCD, psychoaffective and
cognitive measures, and neuroimaging biomarkers (grey
matter atrophy, cerebral glucose hypometabolism, and
amyloid deposition).
Finally, we studied the evolution of the groups over a
mean follow-up period of 2.4 years in terms of SCD,
psychoaffective and cognitive measures, and atrophy
progression over time. We also assessed how baseline
variables predicted subsequent cognitive decline.
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Methods
Subjects
A total of 78 cognitively unimpaired individuals were in-
cluded from the Imagerie Multimodale de la maladie
d’Alzheimer à un stade Précoce (IMAP+) study (Caen,
France). The inclusion and exclusion criteria are detailed
in previous publications. Briefly, participants were all aged
over 50 years; had at least 7 years of education; had no his-
tory of alcoholism, drug abuse, head trauma, or psychiatric
disorder; and performed in the normal range on a stan-
dardized neuropsychological examination [8, 25, 57].
Participants were recruited from two main sources,
memory clinic or public advertising (see Fig. 1). The first
group of SCD patients was recruited from a local mem-
ory clinic consultation (SCD-clinic) that they attended
because of memory concerns. The clinical diagnosis was
obtained by a multidisciplinary consensus under the
supervision of a senior neurologist. The subjective cog-
nitive decline was self-reported to the clinician during
the interview and with a 10-item SCD questionnaire, the
Cognitive Complaint Questionnaire [58]. Before inclu-
sion, the clinician checked that the SCD was not caused
by medication, psychoaffective conditions (including a
major depressive disorder or generalized anxiety dis-
order), or other medical conditions. Amongst the 41 pa-
tients who met these criteria, only those for which the
main variables of interest (self- and informant-reported
SCD questionnaires and objective episodic memory
score) were available were included in the present study,
resulting in a group of 27 SCD-clinic.
Fifty-one participants were recruited from the commu-
nity through public advertising, as they volunteered to
Fig. 1 A flow chart of participant selection and categorization. The graphic shows the steps to select the participants finally included in the three
groups of interest of the present study—the healthy controls and the cognitively unimpaired older adults with subjective cognitive decline (SCD)
who referred (SCD-clinic) or not (SCD-community) to a memory clinic. All participants were selected from the Imagerie Multimodale de la maladie
d’Alzheimer à un stade Précoce (IMAP+) study. N, sample size
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participate in the IMAP+ study. This group was subdivided
into two groups based on their score of self-reported SCD
(see below and Fig. 1) resulting in 28 participants with a
low score considered as the healthy control (HC) and 23
participants with a high score labelled as the SCD-
community. As for the SCD-clinic, only the participants for
whom the three main measures of interest were available
were included in the present study.
The IMAP+ study was approved by the local ethics
committee. After the complete description of the study
to the participants, written informed consent was ob-
tained from all participants.
Neuropsychological assessment
Neuropsychological assessment was performed on the
same site for all participants at baseline and at follow-
up. The mean duration between serial neuropsycho-
logical assessments was 2.4 (± 0.8) years.
Self- and informant-reported cognitive difficulties
SCD was assessed with the Cognitive Difficulties Scale
(CDS) [59], a 39-item self-rated questionnaire that re-
quires participants to rate how often they experience
particular cognitive difficulties in everyday life on a 5-
point scale (from “never” = 0 to “very often” = 4). This
questionnaire was performed by the participant about
himself, resulting in a self-reported measure of SCD, and
by the participant’s informant about the participant,
resulting in an informant-reported measure of SCD.
Higher scores indicate greater SCD.
In the present study, we used the reduced SCD score
of the CDS [59], corresponding to the sum of 34 items,
as a measure of self- or informant-reported cognitive
difficulties. Five items were removed from the initial
questionnaire which correspond to gendered items (e.g.
related to cooking or sewing), as they depend on age-
specific cultural norms [59]. This score will be referred
to as ‘globalR SCD’ in the following article. The self-
reported globalR SCD score was used to separate the HC
from the SCD-community. More specifically, a hierarch-
ical clustering analysis (2 clusters, 50 iterations) was per-
formed on this score within the cognitively unimpaired
volunteers recruited from the community, resulting in
28 participants with a low score (HC) and 23 partici-
pants with a high score (SCD-community).
In a previous study by our team, we conducted a
factorial analysis on the CDS scale and highlighted three
different factors reflecting different types of SCD [56]: (i)
the first factor (F1) was composed of 11 items related to
attention and language; (ii) the second factor (F2)
included 12 items related to memory and orientation;
and (iii) the third factor (F3) included 7 items related to
praxis and domestic activities [56]. These three factors
were computed for each participant using each item
weighted according to the results of the factorial analysis
from La Joie et al. [56] (for self- and informant-reported
SCD) and compared between the groups.
Psychoaffective measures
Depressive symptomatology and trait anxiety were
assessed using the Montgomery-Asberg Depression
Rating Scale (MADRS) [60] and Spielberger State-Trait
Anxiety Inventory (STAI-B), respectively [61]. Higher
scores indicated a higher level of depression or anxiety
with all scores yet keeping within the subclinical levels
as participants were screened for the lack of clinically
significant anxiety or depression disorders.
Cognitive measures
Global cognition was assessed using the Mini-Mental
State Examination (MMSE) [62] and the global score of
the Mattis Dementia Rating Scale (DRS) [63]. Memory
was assessed using the Encoding, Storage and Recuper-
ation (ESR) word list delayed recognition subscores [64].
Cross-sectional data: transformation to w-scores
For cross-sectional analyses, all continuous raw scores
were transformed into w-scores, which are age and
education-adjusted z-scores relative to the control group
[65], except for the psychoaffective measures.
Longitudinal data: computation of slope of changes
For longitudinal analyses, a slope of decline was calculated
for each measure of each subject with a simple linear re-
gression equation ‘y = ax + b’ (where y is the score of inter-
est; x is the number of months from the initial evaluation;
a is the slope of the line; b is the intercept) [66].
Neuroimaging assessment
Neuroimaging data acquisition
All participants were scanned on the same magnetic
resonance imaging (MRI) and positron emission tomog-
raphy (PET) cameras at the Cyceron Center (Caen,
France): a Philips Achieva 3.0 T scanner and a Discovery
RX VCT 64 PET-CT device (General Electric Health-
care), respectively.
High-resolution T1-weighted anatomical volumes were
acquired using a 3D fast-field echo sequence (3D-T1-
FFE sagittal; repetition time = 20ms; echo time = 4.6
ms; flip angle = 10°; 180 slices with no gap; slice thick-
ness = 1 mm; field of view = 256 × 256mm2; in-plane
resolution = 1 × 1mm2). In the present study, we used
the baseline and the follow-up MRI scans; the mean dur-
ation between serial MRI was 2.4 years (± 0.8 years).
Follow-up MRI scan was missing in 1 HC, 1 SCD-
community, and 3 SCD-clinic participants.
Both 18F-fluorodeoxyglucose (FDG) and florbetapir-PET
scans were acquired with a resolution of 3.76 × 3.76 ×
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4.9 mm3 (field of view = 157mm). Forty-seven planes
were obtained with a voxel size of 1.95 × 1.95 × 3.2 mm3.
A transmission scan was performed for attenuation cor-
rection before the PET acquisition. For 18F-FDG-PET, the
participants were fasted for at least 6 h before scanning.
After a 30-min resting period in a quiet and dark environ-
ment, 180MBq of 18F-FDG was intravenously injected as
a bolus. A 10-min PET acquisition scan began 50min after
the injection. For florbetapir-PET, each participant under-
went a 20-min PET scan, beginning 50min after the intra-
venous injections of ~ 4MBq/kg of florbetapir. Two HC
and 3 SCD-clinic participants only underwent a 10-min
acquisition starting 50min after the injection. In the
present study, we used the baseline PET scans of the par-
ticipants, which was missing for 1 HC for 18F-FDG-PET
and for 3 HC and 1 SCD-community participants for
florbetapir-PET (see Additional file 1).
Neuroimaging pre-processing
Cross-sectional data Neuroimaging pre-processing was
performed using the Statistical Parametric Mapping
version 12 (SPM12) software (Wellcome Trust Centre
for Neuroimaging, London, UK).
T1-weighted MRI were segmented using multimodal
segmentation (T1-weighted MRI, T2-weighted MRI, and
Flair) and spatially normalized to the Montreal Neuro-
logical Institute (MNI) space. Then, the normalized grey
matter segments were modulated to correct for non-
linear warping effects, and the resultant images were
smoothed using an 8-mm full-width half-maximum
(FWHM) Gaussian kernel [57, 67, 68].
PET data were corrected for partial volume effects
using the Muller-Gartner method, coregistered onto
their corresponding MRI, and normalized using the de-
formation parameters defined from the MRI procedure.
Resultant images were quantitatively normalized using
the cerebellar grey matter as the reference region. PET
images were then smoothed using a 10-mm FWHM
Gaussian kernel [57, 67–69].
All resultant MRI and PET images were finally masked
to exclude non-grey matter voxels as well as the cerebel-
lum from the analyses.
The global neocortical standardized uptake value ratio
(SUVr) value was also obtained in each individual from
the Florbetapir-PET SUVr images using a neocortex
mask (including all regions but the cerebellum, hippo-
campus, amygdala, and subcortical grey nuclei). The
SUVr was used to classify subjects as florbetapir positive
or negative, using a threshold derived from an independ-
ent group of 41 young individuals from the IMAP pro-
ject (16 females; age = 28.40 ± 6.06 years) [25, 70]. The
positivity threshold was defined by the mean + 2 SD of
41 healthy young controls aged 21 to 39 years old (sup-
posedly devoid of amyloid deposition), corresponding to
a Florbetapir SUVr of 0.98. Individuals with values above
this threshold were considered as amyloid-positive and
those below this threshold as amyloid-negative.
Longitudinal changes For each participant, a brain map
of atrophy progression over time, reflecting the progres-
sion of atrophy over the follow-up period, was computed
using the Jacobian determinants from the pairwise longi-
tudinal registration of the baseline and follow-up MRI
scans. The method is detailed in [71] and summarized in
Additional file 2.
Statistical analysis
Cross-sectional data To assess whether the control and
both SCD groups differ in terms of demographic and
clinical variables or self-reported globalR SCD, variance
analyses (ANOVAs) with one three-level (group) factor
were performed.
To highlight the differences between the three groups
regarding the factors of interest potentially related to
SCD or memory clinic consultation (i.e. psychoaffective
measures, informant-reported SCD, types of SCD), we
performed analyses of covariance (ANCOVAs) with one
three-level (group) factor correcting for age and educa-
tion, for all continuous variables—except for w-scores
where ANOVAs were performed without covariates as
age and education were already partialled out. Group
differences for categorical variables were assessed using
chi-square tests.
The cognitive substrates of self-reported SCD were
assessed in each group using correlations, correcting for
age and education for all variables but w-scores. Correla-
tions were performed between self-reported globalR SCD
score and self-reported SCD factors, informant-reported
globalR SCD, cognitive performances (global cognition
and memory w-scores), and psychoaffective measures
(anxiety and depression). All statistical analyses of be-
havioural data were performed using the STATISTICA
software (v13.0, StatSoft Inc., Tulsa, OK).
The cerebral substrates were assessed in each group
using regression analyses correcting for age and educa-
tion between the self-reported globalR SCD score and
cross-sectional MRI and PET (FDG and Florbetapir)
data. All statistical analyses of neuroimaging data were
performed using the full factorial design in SPM12.
Longitudinal data To determine whether SCD, cogni-
tive, and psychoaffective measures significantly changed
over time, the individual slopes of regression line were
compared to zero for each SCD group separately, using
one-sample t tests. Then, to assess whether the changes
in these measures significantly differed between the
groups, the slopes of regression line were compared be-
tween the groups using ANCOVAs with one two-level
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(group) factor, correcting for age and education, for each
SCD, cognitive, and psychoaffective measures. Thirdly,
to assess whether the atrophy progression over time
significantly differed between the groups, an ANCOVA
with one three-level (group) factor with age and educa-
tion as covariates was performed in SPM12. Finally, to
improve our understanding of the predictors of cognitive
decline, regression analyses were performed within each
SCD group between baseline SCD scores or psychoaffec-
tive measures and the slope of cognitive decline, correct-
ing for age and education, using general linear models
and the STATISTICA software.
Neuroimaging results are examined at puncorrected < 0.005
and cluster extent k > 250mm3 also indicating results sur-
viving the p < 0.001 and k > 50mm3 threshold. This allows
to take into account the clusters that were less significant
but larger versus more significant but smaller. For behav-
ioural results, when the main effect of the group was
significant (p < 0.05), post-hoc analyses were performed
using the Newman-Keuls method.
Results
Group characteristics
There was no between-group difference in any demo-
graphic or cognitive variables; only a trend was found
for SCD-clinic to be younger than HC and SCD-
community to have a higher amyloid proportion of
amyloid-positive individuals (Table 1). The self-reported
globalR SCD score was higher in SCD-clinic compared
to HC but equivalent in both SCD groups (Fig. 2a).
Cross-sectional data
At baseline, the self-reported SCD differed significantly
between the groups for the globalR score and the three
factors. HC showed lower self-reported SCD than both
SCD groups; note that self-reported globalR SCD was used
to separate HC from SCD-community. As for the
informant-reported SCD, SCD-clinic had higher scores
than SCD-community and HC, and SCD-community had
higher scores than HC, for all SCD measures except for
the praxis-domestic activities SCD for which no difference
was found between the SCD groups (see Fig. 2b). The two
psychoaffective measures showed significant between-
group differences: for anxiety, scores were significantly
higher in SCD-community and SCD-clinic compared to
HC; for depression, SCD-clinic had higher scores than
SCD-community and HC (see Fig. 2c, d).
Substrates of self-reported SCD
Cognitive and behavioural correlates
Significant relationships were found between self-
reported globalR SCD score and each self-reported SCD
factors in both SCD groups. Significant correlations were
found between self-reported globalR SCD and the corre-
sponding measures of informant-reported SCD only in
the SCD-clinic. A significant relationship was also found
between the self-reported globalR SCD score and anxiety
in the SCD-community group, while no relationship was
found with baseline objective measures of cognition or
depression in any group (Table 2).
Brain correlates
In the SCD-community group, self-reported globalR SCD
negatively correlated with glucose metabolism and grey
matter volume in the left insula, right superior frontal,
and anterior cingulate cortex (Fig. 3a). Except for the right
superior frontal correlation with grey matter volume, all
Table 1 Demographic features of the study populations
HC SCD-community SCD-clinic ANOVAs, p value
N 28 23 27
Female % (N) 46 (13) 61 (14) 41 (11) (χ2) NS¤
Age 72.25 ± 6.33 71.70 ± 6.60 68.30 ± 7.99 0.09
Level of education 11.50 ± 3.64 12.65 ± 4.13 12.85 ± 3.60 0.37
MMSE 28.68 ± 1.09 28.70 ± 1.18 28.70 ± 1.27 0.99
DRS 0.05 ± 1.02 0.08 ± 0.58 −0.12 ± 0.90 0.68
ESR − 0 ± 0.71 0.01 ± 0.72 − 0.49 ± 1.70 0.18
APOE ε4 (carrier) % (N) 18 (5) 26 (6) 15 (4) (χ2) NS¤
Amyloid status (pos) % (N) 22 (6) 45 (10) 33 (9) (χ2) NS¤
SUVr 0.97 ± 0.17 1.03 ± 0.18 1.01 ± 0.19 0.46
Values indicate mean ± SD or percentage. When the analyses of variance (ANOVAs) reached significance, Newman-Keuls tests were used. ¤For gender, HC – SCD-
community p = 0.29, HC – SCD-clinic p = 0.71, SCD-community – SCD-clinic p = 0.16; for APOE4 carrier: HC – SCD-community p = 0.49, HC – SCD-clinic p = 0.76,
SCD-community – SCD-clinic p = 0.33; for amyloid status: HC – SCD-community 0.09, HC – SCD-clinic p = 0.37, SCD-community – SCD-clinic p = 0.39
Abbreviations: APOE ε4 apolipoprotein E allele 4, DRS w-score of Mattis Dementia Rating Scale, ESR w-score of Encoding, Storage and Recuperation, HC healthy
control, MMSE Mini-Mental State Examination, N sample size, NS not significant, pos positive, SCD subjective cognitive decline, SD standardized deviation
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Fig. 2 Group comparisons on subjective cognitive decline (SCD) and psychoaffective measures. The graphs indicate mean values and 95% confidence
intervals. a Group comparisons on the globalR and the three self-reported SCD factors. b Group comparisons on the globalR and the three informant-
reported SCD factors. c Group comparison on subclinical anxiety. d Group comparison on subclinical depression. a, b p corresponds to one-way analysis of
variance (ANOVA); post-hoc analyses were performed with the Newman-Keuls difference test. Higher scores indicate greater SCD. c, d p corresponds to
one-way analysis of covariance (ANCOVA) correcting for age and education; post-hoc analyses were performed with the Newman-Keuls difference test.
Higher scores indicate higher subclinical anxiety or depression. *p< 0.05, **p< 0.01, ***p< 0.001 between the groups. F1, factor 1 attention-language SCD;
F2, factor 2 memory-orientation SCD; F3, factor 3 praxis-domestic activities SCD; MADRS, Montgomery-Asberg Depression Rating Scale; STAI-B, Spielberger
State-Anxiety Inventory Trait
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clusters were recovered at p < 0.001, k > 50 voxels (Add-
itional file 3).
In the SCD-clinic group, the self-reported globalR
SCD negatively correlated with glucose metabolism in
the bilateral insula, left medial prefrontal cortex
(encompassing both the ventral and dorsal sections), bi-
lateral superior and middle temporal cortex, and right
fusiform gyrus. All clusters were recovered at p < 0.001,
k > 50 voxels, except for the left medial prefrontal cor-
tex (Additional file 3). At the threshold of p < 0.005 and
k > 250 voxels, no correlation was found with amyloid
deposition or grey matter volume (see Fig. 3b).
For the sake of comparison, the correlations were also
assessed with the SCD factors; they showed that the
brain substrates of the self-reported memory SCD score
were very similar to those of the globalR SCD score
(Additional file 3).
Longitudinal data
Cognitive and behavioural measures
The self-reported praxis-domestic activities SCD slope
was significantly higher than zero (p = 0.04), i.e. this
measure significantly increased over time, only in the
SCD-clinic. By contrast, the depression score slope
tended to be higher than zero (p = 0.06) only in the
SCD-community. None of the other slopes significantly
differed from zero indicating that none of the other
self- and informant-reported SCD factors and cognitive
or psychoaffective measures significantly changed over
time during the follow-up period of the SCD groups
(Table 3).
Table 2 Results of linear regressions or general linear models
between self-reported globalR SCD and cross-sectional measures
SCD-community SCD-clinic
r p r p
Self-reported SCD
Attention-language SCD (F1) 0.62 0.003 0.88 < 0.001
Memory-orientation SCD (F2) 0.70 < 0.001 0.90 < 0.001
Praxis-domestic activities SCD (F3) 0.56 0.008 0.67 < 0.001
Informant-reported SCD
GlobalR SCD 0.10 0.66 0.68 < 0.001
Cognitive measures
DRS − 0.10 0.67 0.14 0.48
ESR − 0.25 0.25 − 0.14 0.48
Psychoaffective measures
STAI-B 0.49 0.02 − 0.03 0.90
MADRS − 0.01 0.96 − 0.15 0.47
For the informant-reported SCD and cognitive measures, values indicate the
results of the simple linear regressions (r and p values) between the self-
reported globalR SCD score on the one hand and the corresponding variables
on the other hand. For the psychoaffective measures, values indicate the
results of the general linear model between the self-reported globalR SCD
score and these measures, correcting for age and education. Values indicated
in italics correspond to p < 0.05
Abbreviations: DRS w-score of Mattis Dementia Rating Scale, ESR w-score of
Encoding, Storage and Recuperation, F1 w-score of cognitive difficulties scale
factor 1 attention-language SCD, F2 w-score of cognitive difficulties scale
factor 2 memory-orientation SCD, F3 w-score of cognitive difficulties scale
factor 3 praxis-domestic activities SCD, MADRS Montgomery-Asberg
Depression Rating Scale, SCD subjective cognitive decline, STAI-B Spielberger
State-Anxiety Inventory Trait
A B
Fig. 3 Results of the voxelwise correlations between self-reported globalR SCD and neuroimaging within each SCD group. The correlations with
grey matter volume (blue), glucose metabolism (green), and amyloid deposition (red) are presented within the SCD-community (a) and the SCD-
clinic (b) groups. The results are displayed at uncorrected p < 0.005, k > 250 voxels. FDG, 18F-fluorodeoxyglucose; PET, positron emission
tomography; SCD, subjective cognitive decline
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At follow-up, there was no significant group difference
for any cognitive, psychoaffective, or SCD slope of
changes, except for the self-reported praxis-domestic
activities SCD which increased more in the SCD-clinic
group than in the SCD-community group (Table 3).
Atrophy progression over time in MRI
Between-group comparisons of brain maps of atrophy
progression over time showed that SCD-clinic had
higher atrophy progression over time in the dorsal
frontal cortex compared to HC (Fig. 4b) and in the mid-
dle temporal cortex and dorsal frontal cortex extending
to the ventral prefrontal cortex compared to SCD-
community (Fig. 4c). There was no significant difference
in the atrophy progression over time between HC and
SCD-community (Fig. 4a). All clusters were recovered at
p < 0.001, k > 50 voxels (Additional file 4).
Predictors of cognitive decline
Regression analyses between the slope of cognitive
decline and baseline measures showed that a high
self-reported globalR (r = − 0.59, p = 0.007) or memory
(r = − 0.52, p = 0.02) SCD at baseline correlated with
a higher global cognitive decline only in the SCD-
community group. No baseline measures predicted
the evolution of cognitive performances in the SCD-
clinic group (Additional file 5).
Discussion
The type of recruitment of SCD patients might have a
significant impact on the characteristics, aetiology, and
risk of Alzheimer’s clinical syndrome of the recruited
SCD sample. Yet, the characteristics specifically associ-
ated with help-seeking behaviour in SCD have only been
assessed in a few studies [25, 72–76], and most of these
studies were not restricted to elders with formally
assessed normal cognitive performances, few of them
included the role of the informant or neuroimaging
biomarkers and none included longitudinal data. This
study thus aimed at identifying the characteristics of
SCD individuals according to their type of recruitment
(SCD-community versus SCD-clinic) in terms of cross-
sectional and longitudinal self- and informant-reported
SCD, subclinical anxiety and depression, cognitive per-
formances, and atrophy progression over time, all known
to increase the risk of being at a preclinical stage of
Alzheimer’s syndrome [1, 43, 49–54, 77, 78]. We also
assessed the substrates of self-reported SCD within each
group to identify the main respective drivers of their
Table 3 Description of the progression over time of SCD, cognitive, and psychoaffective measures within each group
Scores N SCD-community N SCD-clinic ANCOVAs, p value
Follow-up duration, years (behavioural measures) 22 2.45 ± 0.67 25 2.36 ± 0.95 0.32
Follow-up duration, years (neuroimaging measures—MRI) 22 2.55 ± 0.67 24 2.28 ± 0.78 0.22
Self-reported SCD slopes
GlobalR 22 − 0.08 ± 0.27 20 0.08 ± 0.35 0.11
Attention-language (F1) 22 0.009 ± 0.06 20 0.02 ± 0.11 0.60
Memory-orientation (F2) 22 − 0.03 ± 0.09 20 0.004 ± 0.12 0.28
Praxis-domestic activities (F3) 22 − 0.009 ± 0.07 20 0.04 ± 0.09# 0.04
Informant-reported SCD slopes
GlobalR 15 0.06 ± 0.46 16 0.07 ± 0.65 0.98
Attention-language (F1) 15 − 0.02 ± 0.13 16 0.01 ± 0.2 0.65
Memory-orientation (F2) 15 0.02 ± 0.12 16 − 0.007 ± 0.12 0.61
Praxis-domestic activities (F3) 15 0.03 ± 0.15 16 0.02 ± 0.1 0.94
Slope of cognitive change
DRS 22 − 0.02 ± 0.14 25 − 0.03 ± 0.11 0.74
ESR 22 0.0005 ± 0.03 24 − 0.02 ± 0.09 0.27
Slope of psychoaffective changes
STAI-B 22 − 0.04 ± 0.21 25 0.05 ± 0.22 0.16
MADRS 22 0.09 ± 0.20 23 0.08 ± 0.26 0.92
The values indicate the mean ± SD of the slope of evolution between baseline and follow-up. When ANCOVAs correcting for age and education reached
significance, values are indicated in italics (p < 0.05)
Abbreviations: ANCOVAs analyses of covariance correcting for age and education, CDS Cognitive Difficulties Scale, DRS Mattis Dementia Rating Scale, ESR Encoding,
Storage and Recuperation, F1 factor 1 attention-language SCD, F2 factor 2 memory-orientation SCD, F3 factor 3 praxis-domestic activities SCD, HC healthy control,
MADRS Montgomery-Asberg Depression Rating Scale, MRI magnetic resonance imaging, N sample size, SCD subjective cognitive decline, SD standardized
deviation, STAI-B Spielberger State-Anxiety Inventory Trait
#The slope is significantly different from zero (p < 0.05)
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SCD which could include risk factor of Alzheimer’s
clinical syndrome [25] or psychological distress [39].
Common points between the SCD groups
The two SCD groups presented similar characteristics,
although the recruitment setting differs. Thus, at a com-
parable level of self-reported globalR SCD, both SCD
groups showed a higher level of subclinical anxiety and a
higher level of informant-reported globalR SCD but simi-
lar cognitive performances compared to controls. Hence,
in both SCD groups, the self-reported globalR SCD
correlated to the three factors—suggesting that they are
not driven by the subjective decline in the distinct cogni-
tive domain—but surprisingly not to any objective meas-
ure of cognition. This highlights the relevance of the
self- and informant-reported SCD, which might be sensi-
tive to subtle cognitive changes not yet detectable using
objective measures [46, 49, 50]. No significant change in
cognition was found in any group, which might reflect
the fact that the follow-up period (2.4 ± 0.8 years) was
too short to capture subtle cognitive decline.
Surprisingly, our findings also showed no difference
between the groups in term of amyloid status or SUVr
uptake values. In contrast to previous studies, the self-
reported SCD was not associated with the presence of
amyloid deposition in cognitively unimpaired elders re-
cruited from the community [18, 20, 21, 23, 25] or in
SCD-clinic patients [22, 25]. However, this effect seems
subtle and might depend on the sample and the meas-
urement used [21, 22], as other studies have reported
negative results like ours [79, 80] compared with con-
trols, or found an association only in APOE ε4 carriers
[81, 82]. Interestingly, when merging our two SCD
groups together, a significant between-group difference
was found with higher amyloid SUVr in the SCD com-
pared to the controls (p = 0.044, Additional file 6). The
lack of difference between the SCD groups might also be
due to the fact that the SCD-clinic tended to be younger
(about 68.3 years old in SCD-clinic against 71.70 in
SCD-community and 72.25 in controls), and the propor-
tion of APOE ε4 carriers was relatively small in the
SCD-clinic (15%) compared to the SCD-community
(26%) or the controls (18%); when the analyses were
Fig. 4 Results of the between-group comparisons of brain maps of atrophy progression over time. Voxelwise comparisons showed the regions of
significantly higher atrophy progression over time in SCD-community as compared to healthy control (HC) (a) and in SCD-clinic as compared to
HC (b) and to SCD-community (c). The results are displayed as T value maps thresholded at uncorrected p < 0.005, k > 250 voxels and as effect
size maps. SCD, subjective cognitive decline
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corrected for age, level of education, and APOE ε4 sta-
tus, a general trend appeared in the between-group com-
parison of amyloid SUVr (p = 0.096, Additional file 6).
Specificities of both SCD groups
Specificities of the SCD-community
While the SCD-community share similarities with the
SCD-clinic, our findings also highlight the differences.
Thus, the SCD-community showed a higher subclinical
anxiety than older adults without subjective cognitive
decline. Moreover, their anxiety score correlated with
their level of self-reported globalR SCD which itself pre-
dicted their subsequent cognitive decline. This suggests
that anxiety contributes to the level of SCD only in the
SCD-community group, while psychoaffective factors do
not influence SCD in the SCD-clinic group. Neuroimag-
ing correlates confirmed this view in showing a link
between SCD and frontal grey matter volume and
glucose metabolism in SCD-community, while it rather
involved the temporal and parietal brain regions sensi-
tive to AD [19, 57, 83] in the SCD-clinic group. As sug-
gested in previous studies [39, 84–86], the subjective
cognitive decline of SCD-community thus seems to be
more strongly related to the psychoaffective factors.
SCD-clinic seems to be a frailer population than SCD-
community
By contrast, a few evidence suggest that SCD-clinic
might be a frailer population than SCD-community.
Thus, cognitively unimpaired older adults with subject-
ive cognitive decline who referred to a memory clinic
were characterized by higher informant-reported globalR
SCD, higher depressive symptoms, and greater subse-
quent atrophy progression over time than those with the
same level of SCD but who did not refer to a memory
clinic. Moreover, SCD-clinic tended to show a more
generalized profile of SCD. Indeed, while their level of
self-reported SCD was similar to SCD-community, they
showed a significant increase in praxis-domestic activ-
ities SCD over the follow-up period.
In a previous study [25], we showed that subclinical
depression and (notably hippocampal) atrophy were spe-
cifically associated with medical help-seeking, suggesting
that those who consult are at a higher risk of developing
Alzheimer’s clinical syndrome, as indicated in another
study which compared the rates of incident dementia
[37]. In the present study, our findings reinforced this
view by showing greater atrophy progression over time.
The atrophy progression over time was significantly
higher in the frontal cortex and tended to be higher in
the temporal lobe and particularly in the hippocampus
(see effect size on Fig. 4). It might thus reflect acceler-
ated brain ageing related to psychoaffective factors, as
the frontal areas are known to be sensitive to ageing
[84–86] and commonly associated with subclinical anx-
iety [87] and depression [88]—themselves associated
with increased risk for cognitive decline or dementia
[27, 33]. These findings might also reflect, to a lesser ex-
tent, increased risk for dementia, as greater hippocampal
atrophy progression over time is known to be associated
with subsequent cognitive decline [89] and dementia
[90]. Similarly, the fact that they showed greater praxis-
domestic activities SCD over time might also represent
an additional evidence for this statement. Thus, as multi-
domain amnestic MCI are known to be more at risk of
AD than single-domain MCI [91], the generalization of
SCD in the SCD-clinic group might alike indicate that
they are in a more advanced stage of SCD and possibly
represent a frailer population than SCD-community, with
an increased risk of cognitive decline, and potentially
Alzheimer’s clinical syndrome. These are yet only indirect
evidences and longer-term follow-up in larger samples are
needed to confirm this hypothesis.
SCD-community and SCD-clinic: a continuum or distinct
entities?
One possible interpretation of our findings is that SCD-
community represents an intermediate stage in a con-
tinuum leading to SCD-clinic. Indeed, they showed inter-
mediate levels of informant-reported globalR SCD, and
their level of subclinical depression tended to increase at
follow-up (p = 0.06), reaching the level of depression of
the SCD-clinic (p = 0.25, data not shown). While their
neural correlates for self-reported globalR SCD were
different from SCD-clinic for some brain regions, there
were also common functional brain correlates (in the in-
sula and frontal cortex) between both SCD groups.
The intermediate level of informant-reported globalR
SCD in the SCD-community highlights the sensitivity of
this measure to capture subtle differences between the
SCD groups that refer or not to a memory clinic. Previ-
ous studies have shown that the informant-reported
SCD can be associated with longitudinal cognitive de-
cline [49] and a higher risk of subsequent conversion to
MCI or AD dementia [50, 92]; suggesting that both
groups show risk factors for Alzheimer’s clinical syn-
drome. Moreover, this is consistent with the fact that the
self-reported SCD measure predicted the level of subse-
quent cognitive decline in the SCD-community, adding
to the risk.
As regards to psychoaffective factors, a higher level of
subclinical anxiety compared to controls characterized
both SCD groups, while the level of subclinical depres-
sion was higher only in the SCD-clinic group at base-
line and increased from baseline to follow-up in the
SCD-community. As a whole, our findings suggest that
referring to a memory clinic is associated with subclin-
ical depression rather than with the level of subclinical
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anxiety or self-reported SCD. Interestingly, both psy-
choaffective factors (depressive symptoms and subclin-
ical anxiety) are frequently associated with early
cognitive deficits [53, 93, 94] or subsequent dementia
[51, 54] and could be a prodromal sign of Alzheimer’s
clinical syndrome [55]. However, the causal link be-
tween self- and informant-reported SCD, psychoaffec-
tive factors, and cognitive or brain changes is unclear.
SCD and frontal atrophy might lead to an increase in
subclinical anxiety and depression, themselves associated
with an increase in informant-reported SCD, leading to
memory consultation. Alternatively, psychoaffective fac-
tors might lead to, or exacerbate, brain and cognitive de-
cline underlying self- and informant-reported SCD and
stimulating memory consultation. Further studies are
needed to better understand the sequence of events and
causal relationships between these different factors. Spe-
cifically, a better understanding of the role of psychoaffec-
tive factors is important for the development of non-
pharmacological interventions targeting emotional regula-
tion processes [95].
Altogether, our results suggest that the two SCD
groups have specificities but may represent in fact differ-
ent stages of progressive cognitive decline that may lead
to Alzheimer’s clinical syndrome. As for early and late
MCI [28, 96], SCD-community and SCD-clinic might
represent two stages of SCD in a continuum that would
lead, for part of them, to Alzheimer’s clinical syndrome.
However, we cannot exclude the alternative hypothesis
that, instead of a continuum, the two groups represent
distinct selections of individuals with SCD where under-
lying neuropsychiatric/non-AD aetiologies versus AD
pathology are differently represented.
Strengths, limitations, and perspectives
The major strengths of this study are its multimodal
dimension and the combination of cross-sectional and
longitudinal setup. Indeed, the availability of standard-
ized assessment of a broad range of factors potentially
related to SCD, including various biomarkers, provides
novel insights into the integrated characterization of
SCD in the context of preclinical AD/Alzheimer’s
syndrome. However, although based on the recommen-
dations of Jessen et al., 2014, which list the specific
features that increase the likelihood of the presence of
preclinical AD/Alzheimer’s syndrome in individuals with
SCD [1, 45] and a previous study [56], the threshold
used to separate SCD-community from controls was
somewhat arbitrary. In addition, all the questionnaires
were self-completed, and the sample sizes and follow-up
time were relatively limited, resulting in a limited
statistical power. Consequently, the statistics were not
corrected for multiple comparisons which increase the
risk for false positive. Therefore, our results should be
interpreted with caution and validated in future studies
with larger group sizes and longer follow-up time. This
would also allow the assessment of the sequential and
causal relationships between the different factors to
understand the role of psychoaffective factors and
informant-reported SCD, but also to confirm that SCD-
community and SCD-clinic are two stages of a con-
tinuum in preclinical Alzheimer’s syndrome. Nowadays,
characterizing and discriminating preclinical Alzheimer’s
syndrome from the ‘worried well’ seems especially import-
ant for the early detection of persons in the preclinical
stage of dementia, the prevention, and the development of
efficient therapies. Given the heterogeneity of the aeti-
ology and presentation of SCD [1, 25, 45, 46], a better un-
derstanding of these two populations might help us to
identify the potential targets for pharmacological or non-
pharmacological interventions.
Conclusions
As a whole, our results point to the SCD-clinic as a frailer
population showing faster atrophy over time, compared to
HC and SCD-community, which might reflect an in-
creased risk for later cognitive decline. Depression symp-
toms were also higher in the SCD-clinic, but they
increased over time in the SCD-community, suggesting a
continuity between SCD groups. Alternatively, they might
reflect distinct populations with different proportion of
possible aetiologies (AD pathology, neuropsychiatric aeti-
ologies, etc.). From a clinical standpoint, SCD patients
might thus benefit from a closer clinical follow-up; from a
research standpoint, this population could enrich inter-
ventional clinical trials on SCD with more participants at
risk of AD/dementia. Finally, our findings highlight the
relevance of psychoaffective factors, including both sub-
clinical anxiety and depression, at this stage. Rather than
confounding factors of SCD, psychoaffective factors might
represent early symptoms of Alzheimer’s clinical syn-
drome, or even the expression of a pathological process
associated with psychological distress and related to sub-
sequent cognitive decline in the SCD-community. This,
along with the fact that they are associated with increased
risk of dementia, highlights the relevance of treating these
symptoms in the elderly. Further studies are yet needed to
better understand their causal and/or consequent role
within the different SCD stages.
Additional files
Additional file 1: Population sizes at the various imaging examination
time points: cross-sectional and longitudinal neuroimaging assessments.
Abbreviations: HC healthy control, SCD subjective cognitive decline, N
sample size, MRI magnetic resonance imaging, PET positron emission
tomography, FDG 18F-fluorodeoxyglucose. (DOCX 46 kb)
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Additional file 2: Description of the methodology of the longitudinal
neuroimaging data processing. (DOCX 16 kb)
Additional file 3: Glass brain of the voxelwise correlations between self-
reported SCD and neuroimaging within each SCD group. The correlations
between self-reported SCD measures (1, GlobalR SCD; 2, Attention/Language
SCD; 3, Memory/Orientation SCD; 4, Praxis/Domestic Activities SCD) and
grey matter volume (MRI), glucose metabolism (FDG-PET), or amyloid
deposition (Florbetapir-PET) are presented within the SCD-community (A)
and the SCD-clinic (B) groups. The results are displayed at uncorrected p <
0.005, k > 250 voxels and p < 0.001, k > 50 voxels for all analyses. FDG 18F-
fluorodeoxyglucose, PET positron emission tomography, SCD subjective
cognitive decline. (DOCX 538 kb)
Additional file 4: Glass brains of the between-group comparisons of
brain maps of atrophy progression over time. Voxelwise comparisons
show the regions of significantly higher atrophy progression over time in
SCD-community as compared to healthy control (HC) (A), and in SCD-
clinic as compared to HC (B) and to SCD-community (C). The results are
displayed as T value maps thresholded at uncorrected p < 0.005, k > 250
voxels and p < 0.001, k > 50 voxels. SCD Subjective cognitive decline.
(DOCX 267 kb)
Additional file 5: Results of the general linear model assessing the links
between baseline variables and cognitive decline slopes. The values
indicate the results of the general linear model assessing the links
between baseline self- and informant-reported SCD factors or
psychoaffective measures and the slope of cognitive decline, corrected
for age and education. Values indicated in bold correspond to p < 0.05.
Abbreviations: DRS Mattis Dementia Rating Scale, ESR Encoding, Storage
and Recuperation, F1 score of cognitive difficulties scale factor 1
attention-language SCD, F2 score of cognitive difficulties scale factor 2
memory-orientation SCD, F3 score of cognitive difficulties scale factor 3
praxis-domestic activities SCD, MADRS Montgomery-Asberg Depression
Rating Scale, SCD subjective cognitive decline, STAI-B Spielberger State-
Anxiety Inventory Trait. (DOCX 21 kb)
Additional file 6: Group comparisons on amyloid SUVr. Graphs indicate
mean values and 95% confidence intervals. A: three-group comparisons
on the amyloid SUVr and post-hoc analyses performed with the
Newman-Keuls test; B: two-group comparisons on the amyloid SUVr,
when SCD groups were merged. ANCOVA analysis of variance corrected,
APOE apolipoprotein E, HC healthy control, SCD subjective cognitive de-
cline, SUVr standardized uptake value ratio. (DOCX 77 kb)
Abbreviations
AD: Alzheimer’s disease; ANCOVA: Analysis of covariance; ANOVA: Analysis of
variance; APOE ε4: Apolipoprotein E allele 4; Aβ: Amyloid deposition;
CDS: Cognitive Difficulties Scale; DRS: Mattis Dementia Rating Scale;
ESR: Encoding, Storage and Recuperation; F1: Factor 1 of CDS corresponding
to attention-language SCD; F2: Factor 2 of CDS corresponding to memory-
orientation SCD; F3: Factor 3 of CDS corresponding to praxis-domestic activ-
ities SCD; FDG: 18F-fluorodeoxyglucose; FWHM: Full-width half-maximum;
HC: Healthy controls; IMAP+: Imagerie Multimodale de la maladie d’Alzheimer
Précoce; MADRS: Montgomery-Asberg Depression Rating Scale; MCI: Mild
cognitive impairment; MMSE: Mini-Mental State Examination; MNI: Montreal
Neurological Institute; MRI: Magnetic resonance imaging; N: Size; NS: Not
significant; PET: Positron emission tomography; Pos: Positive; SCD: Subjective
cognitive decline; SCD-clinic: Subjective cognitive decline recruited from a
memory clinic; SCD-community: Subjective cognitive decline recruited from
volunteers from the community; SCD-I: Subjective Cognitive Decline
Initiative; SD: Standard deviation; SPM12: Statistical Parametric Mapping
version 12; STAI-B: Spielberger State-Trait Anxiety Inventory-B;
SUVr: Standardized uptake value ratio
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Acknowledgements
The authors thank F. Eustache, E. Arenaza-Urquijo, J. Gonneaud, R. De Flores,
J. Mutlu, C. André, V. Ourry, F. Mézenge, M. Leblond, T. Anquetil, K. Mevel, N.
Villain, M. Fouquet, A. Quillard, C. Schupp, J. Dayan, A. Chocat, JC. Baron, F.
Viader, A. Pélerin, M. Gaubert, S. Egret, M. Delarue, G. Rauchs, A. Abbas, L.
Barre, A. Manrique, D. Guilloteau, and the Cyceron staff members for their
help with the data acquisition and the volunteers who were included in this
study.
Authors’ contributions
EK and IM performed the analyses, contributed to the data interpretation, and
wrote the first draft of the manuscript. AP, BL, CT, and RLJ contributed to the
design of the study, data acquisition and interpretation, and manuscript
revision. AB and SS contributed to the neuroimaging data processing,
interpretation, and manuscript revision. VDLS is the main MD investigator, he
supervised the recruitment of the patients, and participated in the study design
and data interpretation. BD, DV, and GP participated in study design, data
interpretation, and/or manuscript revision. GC is the principal investigator of
IMAP and she supervised the study, the interpretation of data, and the writing
of the manuscript. All authors read and approved the final manuscript.
Funding
The study was supported by Fondation Plan Alzheimer (Alzheimer Plan
2008–2012), Programme Hospitalier de Recherche Clinique (PHRCN 2011-
A01493-38 and PHRCN 2012 12-006-0347), Agence Nationale de la Recherche
(LONGVIE 2007), Région Basse-Normandie, Association France Alzheimer et
maladies apparentées AAP 2013, the Institut National de la Santé et de la
Recherche Médicale (INSERM), and the University of Caen Normandy. The
funding sources were not involved in the study design, data acquisition, data
analysis, or article writing.
Availability of data and materials
The datasets generated and analysed during the current study are not
publicly available due to local privacy regulations but are available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
The IMAP study was approved by the regional ethics committee (Comité de
Protection des Personnes Nord-Ouest III) and registered with ClinicalTrials.
gov (number NCT01638949). All participants gave written informed consent




The authors declare that they have no competing interests.
Author details
1Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie,
Boulevard H. Becquerel, 14000 Caen, France. 2Memory and Aging Center,
Department of Neurology, University of California, San Francisco, San
Francisco, CA, USA. 3Normandie Univ, UNICAEN, PSL Recherche Universités,
EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie et Imagerie de la
Mémoire Humaine, GIP Cyceron, 14000 Caen, France. 4CHU de Caen, Service
de Neurologie, Caen, France. 5Department of Clinical Research, Caen
Normandy Hospital (CHU) de Caen, 14000 Caen, France.
Received: 20 December 2018 Accepted: 13 June 2019
References
1. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et
al. A conceptual framework for research on subjective cognitive decline in
preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52. https://
doi.org/10.1016/j.jalz.2014.01.001.
2. Reisberg B, Ferris SH, De L, Crook T. The global deterioration scale for assessment
of primary degenerative dementia. Am J Psychiatry. 1982;139:1136–9.
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al.
Toward defining the preclinical stages of Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.
4. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al.
Preclinical Alzheimer’s disease: definition, natural history, and diagnostic
Kuhn et al. Alzheimer's Research & Therapy           (2019) 11:61 Page 13 of 16
criteria. Alzheimers Dement. 2016;12:292–323. https://doi.org/10.1016/j.jalz.
2016.02.002.
5. Scheef L, Spottke A, Daerr M, Joe A, Striepens N, Kölsch H, et al. Glucose
metabolism, gray matter structure, and memory decline in subjective
memory impairment. Neurology. 2012;79:1332–9.
6. Stewart R, Dufouil C, Godin O, Ritchie K, Maillard P, Delcroix N, et al.
Neuroimaging correlates of subjective memory deficits in a community
population. Neurology. 2008;70:1601–7. https://doi.org/10.1212/01.wnl.
0000310982.99438.54.
7. Van Der Flier W, Van Buchem M, Weverling-Rijnsburger AWE, Mutsaers ER,
Bollen ELEM, Admiraal-Behloul F, et al. Memory complaints in patients with
normal cognition are associated with smaller hippocampal volumes. J
Neurol. 2004;251:671–5.
8. Perrotin A, de Flores R, Lamberton F, Poisnel G, La Joie R, de la Sayette V, et
al. Hippocampal subfield volumetry and 3D surface mapping in subjective
cognitive decline. J Alzheimers Dis. 2015;48:S141–50. https://doi.org/10.
3233/JAD-150087.
9. Striepens N, Scheef L, Wind A, Popp J, Spottke A, Cooper-Mahkorn D, et al.
Volume loss of the medial temporal lobe structures in subjective memory
impairment. Dement Geriatr Cogn Disord. 2010;29:75–81. https://doi.org/10.
1159/000264630.
10. Hafkemeijer A, Altmann-Schneider I, Oleksik AM, van de Wiel L, Middelkoop
HAM, van Buchem MA, et al. Increased functional connectivity and brain
atrophy in elderly with subjective memory complaints. Brain Connect. 2013;
3:353–62. https://doi.org/10.1089/brain.2013.0144.
11. Jessen F, Feyen L, Freymann K, Tepest R, Maier W, Heun R, et al. Volume
reduction of the entorhinal cortex in subjective memory impairment.
Neurobiol Aging. 2006;27:1751–6.
12. Peter J, Scheef L, Abdulkadir A, Boecker H, Heneka M, Wagner M, et al. Gray
matter atrophy pattern in elderly with subjective memory impairment.
Alzheimers Dement J Alzheimers Assoc. 2014;10:99–108.
13. Schultz SA, Oh JM, Koscik RL, Dowling NM, Gallagher CL, Carlsson CM, et al.
Subjective memory complaints, cortical thinning, and cognitive dysfunction
in middle-age adults at risk of AD. Alzheimers Dement Diagn Assess Dis
Monit. 2015;1:33–40. https://doi.org/10.1016/j.dadm.2014.11.010.
14. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al.
Older adults with cognitive complaints show brain atrophy similar to that of
amnestic MCI. Neurology. 2006;67:834–42. https://doi.org/10.1212/01.wnl.
0000234032.77541.a2.
15. van Norden AGW, Fick WF, de Laat KF, van Uden IWM, van Oudheusden
LJB, Tendolkar I, et al. Subjective cognitive failures and hippocampal volume
in elderly with white matter lesions. Neurology. 2008;71:1152–9.
16. Kim M-J, Seo SW, Kim GH, Kim ST, Lee J-M, Qiu A, et al. Less depressive
symptoms are associated with smaller hippocampus in subjective memory
impairment. Arch Gerontol Geriatr. 2013;57:110–5. https://doi.org/10.1016/j.
archger.2013.01.005.
17. Cantero JL, Iglesias JE, Van Leemput K, Atienza M. Regional hippocampal
atrophy and higher levels of plasma amyloid-beta are associated with
subjective memory complaints in nondemented elderly subjects. J Gerontol
Ser A. 2016;71:1210–5. https://doi.org/10.1093/gerona/glw022.
18. Amariglio RE, Mormino EC, Pietras AC, Marshall GA, Vannini P, Johnson KA,
et al. Subjective cognitive concerns, amyloid-β, and neurodegeneration in
clinically normal elderly. Neurology. 2015;85:56–62. https://doi.org/10.1212/
WNL.0000000000001712.
19. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska
L, et al. Hypometabolism and altered cerebrospinal fluid markers in
normal apolipoprotein E E4 carriers with subjective memory
complaints. Biol Psychiatry. 2008;63:609–18. https://doi.org/10.1016/j.
biopsych.2007.05.030.
20. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, et
al. Subjective cognitive complaints and amyloid burden in cognitively
normal older individuals. Neuropsychologia. 2012;50:2880–6. https://doi.org/
10.1016/j.neuropsychologia.2012.08.011.
21. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective
cognition and amyloid deposition imaging: a Pittsburgh compound B
positron emission tomography study in normal elderly individuals. Arch
Neurol. 2012;69:223–9. https://doi.org/10.1001/archneurol.2011.666.
22. Snitz BE, Lopez OL, McDade E, Becker JT, Cohen AD, Price JC, et al. Amyloid-
β imaging in older adults presenting to a memory clinic with subjective
cognitive decline: a pilot study. J Alzheimers Dis. 2015;48:S151–9. https://doi.
org/10.3233/JAD-150113.
23. Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, et al.
Subjective cognitive complaints, personality and brain amyloid-beta in
cognitively normal older adults. Am J Geriatr Psychiatry. 2015;23:985–93.
https://doi.org/10.1016/j.jagp.2015.01.008.
24. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, et al.
Indicators of amyloid burden in a population-based study of cognitively
normal elderly. Neurology. 2012;79:1570–7. https://doi.org/10.1212/WNL.
0b013e31826e2696.
25. Perrotin A, La Joie R, de La Sayette V, Barré L, Mézenge F, Mutlu J, et al.
Subjective cognitive decline in cognitively normal elders from the community
or from a memory clinic: differential affective and imaging correlates.
Alzheimers Dement. 2017;13:550–60. https://doi.org/10.1016/j.jalz.2016.08.011.
26. Kaup AR, Nettiksimmons J, LeBlanc ES, Yaffe K. Memory complaints and risk
of cognitive impairment after nearly 2 decades among older women.
Neurology. 2015;85:1852–8. https://doi.org/10.1212/WNL.0000000000002153.
27. Koppara A, Wagner M, Lange C, Ernst A, Wiese B, König H-H, et al. Cognitive
performance before and after the onset of subjective cognitive decline in
old age. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:194–205.
https://doi.org/10.1016/j.dadm.2015.02.005.
28. Jessen F, Wolfsgruber S, Wiese B, Bickel H, Mösch E, Kaduszkiewicz H, et al. AD
dementia risk in late MCI, in early MCI, and in subjective memory impairment.
Alzheimers Dement. 2014;10:76–83. https://doi.org/10.1016/j.jalz.2012.09.017.
29. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven
years of healthy adults with and without subjective cognitive impairment.
Alzheimers Dement J Alzheimers Assoc. 2010;6. https://doi.org/10.1016/j.jalz.
2009.10.002.
30. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of
dementia and mild cognitive impairment in older people with subjective
memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130:439–51.
https://doi.org/10.1111/acps.12336.
31. Rönnlund M, Sundström A, Adolfsson R, Nilsson L-G. Subjective memory
impairment in older adults predicts future dementia independent of
baseline memory performance: evidence from the Betula prospective
cohort study. Alzheimers Dement. 2015;11:1385–92. https://doi.org/10.1016/
j.jalz.2014.11.006.
32. Wang L, van Belle G, Crane PK, Kukull WA, Bowen JD, McCormick WC, et al.
Subjective memory deterioration and future dementia in people aged 65
and older. J Am Geriatr Soc. 2004;52:2045–51.
33. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, et al.
Prediction of dementia by subjective memory impairment: effects of
severity and temporal association with cognitive impairment. Arch Gen
Psychiatry. 2010;67:414–22.
34. Nunes T, Fragata I, Ribeiro F, Palma T, Maroco J, Cannas J, et al. The
outcome of elderly patients with cognitive complaints but normal
neuropsychological tests. J Alzheimers Dis JAD. 2010;19:137–45.
35. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.
NIA-AA Research Framework: toward a biological definition of Alzheimer’s
disease. Alzheimers Dement J Alzheimers Assoc. 2018;14:535–62.
36. Blackburn DJ, Wakefield S, Shanks MF, Harkness K, Reuber M, Venneri A.
Memory difficulties are not always a sign of incipient dementia: a review of
the possible causes of loss of memory efficiency. Br Med Bull. 2014;112:71–
81. https://doi.org/10.1093/bmb/ldu029.
37. Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al.
Subjective cognitive decline and rates of incident Alzheimer’s disease and
non–Alzheimer’s disease dementia. Alzheimers Dement J Alzheimers Assoc.
2018;0. https://doi.org/10.1016/j.jalz.2018.10.003.
38. Ponds RW, Commissaris KJ, Jolles J. Prevalence and covariates of subjective
forgetfulness in a normal population in The Netherlands. Int J Aging Hum
Dev. 1997;45:207–21.
39. Comijs HC, Deeg DJH, Dik MG, Twisk JWR, Jonker C. Memory complaints;
the association with psycho-affective and health problems and the role of
personality characteristics: a 6-year follow-up study. J Affect Disord. 2002;72:
157–65. https://doi.org/10.1016/S0165-0327(01)00453-0.
40. Clarnette RM, Almeida OP, Forstl H, Paton A, Martins RN. Clinical characteristics
of individuals with subjective memory loss in Western Australia: results from a
cross-sectional survey. Int J Geriatr Psychiatry. 2001;16:168–74.
41. Kang S-H, Yoon I-Y, Lee SD, Kim T, Lee CS, Han JW, et al. Subjective memory
complaints in an elderly population with poor sleep quality. Aging Ment
Health. 2017;21:532–6.
42. Gamaldo AA, Wright RS, Aiken-Morgan AT, Allaire JC, Thorpe RJ, Whitfield
KE. The association between subjective memory complaints and sleep
Kuhn et al. Alzheimer's Research & Therapy           (2019) 11:61 Page 14 of 16
within older African American adults. J Gerontol Ser B. 2019;74:202–11.
https://doi.org/10.1093/geronb/gbx069.
43. Lauriola M, Esposito R, Pizzi SD, de Zambotti M, Londrillo F, Kramer JH, et al.
Sleep changes without medial temporal lobe or brain cortical changes in
community-dwelling individuals with subjective cognitive decline.
Alzheimers Dement J Alzheimers Assoc. 2017;13:783–91. https://doi.org/10.
1016/j.jalz.2016.11.006.
44. Paradise MB, Glozier NS, Naismith SL, Davenport TA, Hickie IB. Subjective
memory complaints, vascular risk factors and psychological distress in the
middle-aged: a cross-sectional study. BMC Psychiatry. 2011;11:108.
45. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al.
Implementation of subjective cognitive decline criteria in research studies.
Alzheimers Dement J Alzheimers Assoc. 2017;13:296–311. https://doi.org/10.
1016/j.jalz.2016.09.012.
46. Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical
Alzheimer’s disease. Annu Rev Clin Psychol. 2017;13:369–96.
47. Rodríguez-Gómez O, Abdelnour C, Jessen F, Valero S, Boada M. Influence of
sampling and recruitment methods in studies of subjective cognitive decline. J
Alzheimers Dis. 2015;48:S99–107. https://doi.org/10.3233/JAD-150189.
48. Archer HA, Newson MA, Coulthard EJ. Subjective memory complaints:
symptoms and outcome in different research settings. J Alzheimers Dis.
2015;48:S109–14. https://doi.org/10.3233/JAD-150108.
49. Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, et
al. Tracking early decline in cognitive function in older individuals at risk for
Alzheimer’s disease dementia: the Alzheimer’s Disease Cooperative Study
Cognitive Function Instrument. JAMA Neurol. 2015;72:446–54. https://doi.
org/10.1001/jamaneurol.2014.3375.
50. Caselli RJ, Chen K, Locke DEC, Lee W, Roontiva A, Bandy D, et al. Subjective
cognitive decline: self and informant comparisons. Alzheimers Dement J
Alzheimers Assoc. 2014;10:93–8.
51. Wilson RS, Begeny CT, Boyle PA, Schneider JA, Bennett DA. Vulnerability to
stress, anxiety, and development of dementia in old age. Am J Geriatr
Psychiatry. 2011;19:327–34. https://doi.org/10.1097/JGP.0b013e31820119da.
52. Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, et al.
Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a
multicenter, prospective cohort study. JAMA Psychiatry. 2015;72:284–91.
https://doi.org/10.1001/jamapsychiatry.2014.2476.
53. Yochim BP, Mueller AE, Segal DL. Late life anxiety is associated with
decreased memory and executive functioning in community dwelling older
adults. J Anxiety Disord. 2013;27:567–75.
54. Kaup AR, Byers AL, Falvey C, Simonsick EM, Satterfield S, Ayonayon HN, et al.
Trajectories of depressive symptoms in older adults and risk of dementia. JAMA
Psychiatry. 2016;73:525–31. https://doi.org/10.1001/jamapsychiatry.2016.0004.
55. Donovan NJ, Hsu DC, Dagley AS, Schultz AP, Amariglio RE, Mormino EC, et
al. Depressive symptoms and biomarkers of Alzheimer’s disease in
cognitively normal older adults. J Alzheimers Dis JAD. 2015;46:63–73.
56. La Joie R, Perrotin A, Egret S, Pasquier F, Tomadesso C, Mézenge F, et al.
Qualitative and quantitative assessment of self-reported cognitive difficulties
in nondemented elders: association with medical help seeking, cognitive
deficits, and β-amyloid imaging. Alzheimers Dement Diagn Assess Dis
Monit. 2016;5:23–34. https://doi.org/10.1016/j.dadm.2016.12.005.
57. La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, et al.
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid
(Aβ) load in Alzheimer’s disease dementia. J Neurosci. 2012;32:16265–73.
https://doi.org/10.1523/JNEUROSCI.2170-12.2012.
58. Anterion CT, Ribas C, Honoré-Masson S, Berne G, Ruel JH, Laurent B. Le
questionnaire de plainte cognitive (QPC): un outil de recherche de plainte
suspecte d’évoquer une maladie d’Alzheimer? [Cognitive Complaint
Questionnaire. L’Année Gérontologique. 2003. p. 56–65. http://www.bdsp.
ehesp.fr/Base/277296/.
59. McNair D, Kahn R. Self-assessment of cognitive deficits. Assessment in
geriatric psychopharmacology 119–36. Assessment in geriatric
psychopharmacology; 1983.
60. Montgomery SA, Asberg M. A new depression scale designed to be
sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382–9.
61. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the state-trait anxiety
inventory. 1970. https://ubir.buffalo.edu/xmlui/handle/10477/2895. Accessed
28 Sept 2018.
62. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method
for grading the cognitive state of patients for the clinician. J Psychiatr Res.
1975;12:189–98. https://doi.org/10.1016/0022-3956(75)90026-6.
63. Mattis S. Mental status examination for organic mental syndrome in the
elderly patients. In: Geriatric psychiatry: a handbook for psychiatrists and
primary care physicians; 1976. p. 77–121.
64. Eustache F, Laisney M, Lalevée C, Pèlerin A, Perrotin A, Egret S, et al. Une
nouvelle épreuve de mémoire épisodique : l’épreuve ESR-forme réduite
(ESR-r), adaptée du paradigme ESR (encodage, stockage, récupération), A
new episodic memory task: the short-ESR (s-ESR) task adapted from the
Encoding Storage Retrieval paradigm. Rev Neuropsychol. 2015;7:217–25.
https://doi.org/10.1684/nrp.2015.0351.
65. Boccardi M, Laakso MP, Bresciani L, Galluzzi S, Geroldi C, Beltramello A, et al.
The MRI pattern of frontal and temporal brain atrophy in fronto-temporal
dementia. Neurobiol Aging. 2003;24:95–103.
66. Chételat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, et
al. FDG-PET measurement is more accurate than neuropsychological
assessments to predict global cognitive deterioration in patients with mild
cognitive impairment. Neurocase. 2005;11:14–25.
67. Villain N, Desgranges B, Viader F, de la SV, Mézenge F, Landeau B, et al.
Relationships between hippocampal atrophy, white matter disruption, and
gray matter hypometabolism in Alzheimer’s disease. J Neurosci. 2008;28:
6174–81. https://doi.org/10.1523/JNEUROSCI.1392-08.2008.
68. Chételat G, Desgranges B, Landeau B, Mézenge F, Poline JB, de la
Sayette V, et al. Direct voxel-based comparison between grey matter
hypometabolism and atrophy in Alzheimer’s disease. Brain J Neurol.
2008;131(Pt 1):60–71.
69. Bejanin A, La Joie R, Landeau B, Belliard S, de La Sayette V, Eustache F, et al.
Distinct interplay between atrophy and hypometabolism in Alzheimer’s
versus semantic dementia. Cereb Cortex. 2019;29:1889-99. https://doi:10.
1093/cercor/bhy069
70. Besson FL, Joie RL, Doeuvre L, Gaubert M, Mézenge F, Egret S, et al.
Cognitive and brain profiles associated with current neuroimaging
biomarkers of preclinical Alzheimer’s disease. J Neurosci. 2015;35:10402–11.
https://doi.org/10.1523/JNEUROSCI.0150-15.2015.
71. Mutlu J, Landeau B, Gaubert M, de La Sayette V, Desgranges B, Chételat G.
Distinct influence of specific versus global connectivity on the different
Alzheimer’s disease biomarkers. Brain J Neurol. 2017;140:3317–28.
72. Ramakers IHGB, Visser PJ, Bittermann AJN, Ponds RWHM, van Boxtel MPJ,
Verhey FRJ. Characteristics of help-seeking behaviour in subjects with
subjective memory complaints at a memory clinic: a case-control study. Int
J Geriatr Psychiatry. 2009;24:190–6.
73. Jorm AF, Butterworth P, Anstey KJ, Christensen H, Easteal S, Maller J, et al.
Memory complaints in a community sample aged 60-64 years: associations
with cognitive functioning, psychiatric symptoms, medical conditions, APOE
genotype, hippocampus and amygdala volumes, and white-matter
hyperintensities. Psychol Med. 2004;34:1495–506.
74. Begum A, Whitley R, Banerjee S, Matthews D, Stewart R, Morgan C. Help-
seeking response to subjective memory complaints in older adults: toward
a conceptual model. The Gerontologist. 2013;53:462–73.
75. Hurt CS, Burns A, Brown RG, Barrowclough C. Why don’t older adults with
subjective memory complaints seek help? Int J Geriatr Psychiatry. 2012;27:394–400.
76. Werner P. Beliefs about memory problems and help seeking in elderly
persons. Clin Gerontol. 2004;27:19–30.
77. da Silva RAPC. Sleep disturbances and mild cognitive impairment: a review.
Sleep Sci. 2015;8:36–41. https://doi.org/10.1016/j.slsci.2015.02.001.
78. Hita-Yañez E, Atienza M, Cantero JL. Polysomnographic and subjective sleep
markers of mild cognitive impairment. Sleep. 2013;36:1327–34.
79. Buckley R, Saling MM, Ames D, Rowe CC, Lautenschlager NT, Macaulay SL,
et al. Factors affecting subjective memory complaints in the AIBL aging
study: biomarkers, memory, affect, and age. Int Psychogeriatr. 2013;25:1307–
15. https://doi.org/10.1017/S1041610213000665.
80. Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, et al.
Amyloid-β related memory decline is not associated with subjective or
informant rated cognitive impairment in healthy adults. J Alzheimers Dis.
2015;43:677–86.
81. Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, et al.
Subjective memory complaints in APOE ɛ4 carriers are associated with high
amyloid-β burden. J Alzheimers Dis. 2016;49:1115–22. https://doi.org/10.
3233/JAD-150446.
82. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid
imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL)
study of aging. Neurobiol Aging. 2010;31:1275–83. https://doi.org/10.1016/j.
neurobiolaging.2010.04.007.
Kuhn et al. Alzheimer's Research & Therapy           (2019) 11:61 Page 15 of 16
83. Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain
atrophy in Alzheimer’s disease and aging. Ageing Res Rev. 2016;30:25–48.
https://doi.org/10.1016/j.arr.2016.01.002.
84. Chételat G, Mézenge F, Tomadesso C, Landeau B, Arenaza-Urquijo E, Rauchs
G, et al. Reduced age-associated brain changes in expert meditators: a
multimodal neuroimaging pilot study. Sci Rep. 2017;7. https://doi.org/10.
1038/s41598-017-07764-x.
85. Fjell AM, Walhovd KB. Structural brain changes in aging: courses, causes and
cognitive consequences. Rev Neurosci. 2010;21:187–221.
86. Kalpouzos G, Chételat G, Baron J-C, Landeau B, Mevel K, Godeau C, et al.
Voxel-based mapping of brain gray matter volume and glucose metabolism
profiles in normal aging. Neurobiol Aging. 2009;30:112–24.
87. Spampinato MV, Wood JN, De Simone V, Grafman J. Neural correlates of
anxiety in healthy volunteers: a voxel-based morphometry study. J
Neuropsychiatry Clin Neurosci. 2009;21:199–205.
88. Du M-Y, Wu Q-Z, Yue Q, Li J, Liao Y, Kuang W-H, et al. Voxelwise meta-
analysis of gray matter reduction in major depressive disorder. Prog Neuro-
Psychopharmacol Biol Psychiatry. 2012;36:11–6. https://doi.org/10.1016/j.
pnpbp.2011.09.014.
89. Aljondi R, Szoeke C, Steward C, Yates P, Desmond P. A decade of changes
in brain volume and cognition. Brain Imaging Behav. 2018. https://doi.org/
10.1007/s11682-018-9887-z.
90. den Heijer T, van der Lijn F, Koudstaal PJ, Hofman A, van der Lugt A, Krestin
GP, et al. A 10-year follow-up of hippocampal volume on magnetic
resonance imaging in early dementia and cognitive decline. Brain J Neurol.
2010;133(Pt 4):1163–72.
91. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al.
2014 update of the Alzheimer’s Disease Neuroimaging Initiative: a review of
papers published since its inception. Alzheimers Dement J Alzheimers
Assoc. 2015;11:e1–120. https://doi.org/10.1016/j.jalz.2014.11.001.
92. Gifford KA, Liu D, Lu Z, Tripodis Y, Cantwell NG, Palmisano J, et al. The
source of cognitive complaints predicts diagnostic conversion differentially
among nondemented older adults. Alzheimers Dement. 2014;10:319–27.
https://doi.org/10.1016/j.jalz.2013.02.007.
93. Balash Y, Mordechovich M, Shabtai H, Giladi N, Gurevich T, Korczyn AD.
Subjective memory complaints in elders: depression, anxiety, or cognitive
decline? Acta Neurol Scand. 2013;127:344–50. https://doi.org/10.1111/ane.12038.
94. Bierman EJM, Comijs HC, Jonker C, Beekman ATF. Symptoms of anxiety and
depression in the course of cognitive decline. Dement Geriatr Cogn Disord.
2007;24:213–9. https://doi.org/10.1159/000107083.
95. Innes KE, Selfe TK. Meditation as a therapeutic intervention for adults at risk
for Alzheimer’s disease – potential benefits and underlying mechanisms.
Front Psychiatry. 2014;5. https://doi.org/10.3389/fpsyt.2014.00040.
96. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al.
Clinical core of the Alzheimer’s disease neuroimaging initiative: progress
and plans. Alzheimers Dement. 2010;6:239–46. https://doi.org/10.1016/j.jalz.
2010.03.006.
Kuhn et al. Alzheimer's Research & Therapy           (2019) 11:61 Page 16 of 16
